Pharmalot... Pharmalittle... Good Morning

Good morning, everyone, and how are you today? We are just fine, thank you, although as busy as ever, thanks to a calendar brimming with meetings and phone calls this week. In fact, we will be leaving a wee bit early today in order to chat with a high-level type at a large company. More on that later. Meanwhile, here are some tidbits, as usual, which we trust you will find useful. So, have a smashing day and do stay in touch... Bayer Is Latest Target In China Bribery Probe (South China Morning Post) Bristol's Yervoy Drug Falls Short In Prostate Cancer Study (Reuters) Genentech Aims For Precedent With FDA OK For Breast Cancer Drug (Xconomy) Ranbaxy Plants Reveal Minor Deficiences In Preliminary Report (MoneyControl) J&J Recalls Some Risperdal Consta After Discovering Mold (Reuters) China's Sino Biopharmaceuticals Is Accused Of Bribery (The Wall Street Journal) Glaxo Remains Upbeat, Despite China Woes (Bloomberg News) Hospira Is Set To Launch Biosimilar Remicade In Europe (Pharma Times)...Read more
Source: Pharmalot - Category: Pharma Commentators Authors: Source Type: blogs